Distinguished in WT1-Related Wilms Tumor Syndromes

Dr. Harriet Kluger

Hematology | Oncology
Yale New Haven Health System
Yale University
20 York St, 
New Haven, CT 
Offers Telehealth

Distinguished in WT1-Related Wilms Tumor Syndromes
Yale New Haven Health System
Yale University
20 York St, 
New Haven, CT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Harriet Kluger is a Hematologist and an Oncologist in New Haven, Connecticut. Dr. Kluger is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Melanoma, Merkel Cell Carcinoma, Renal Cell Carcinoma (RCC), Melanoma of the Eye, and Nephrectomy.

Her clinical research consists of co-authoring 248 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in CT
Hospital Affiliations
Yale-New Haven Hospital
Bridgeport Hospital
Lawrence & Memorial Hospital
Greenwich Hospital Association -
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

YALE UNIVERSITY
20 York St, New Haven, CT 06510
Call: 203-688-4242
Other Locations
YALE UNIVERSITY
800 Howard Ave, New Haven, CT 06519
Call: 203-785-2140

Additional Areas of Focus

Dr. Kluger has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


10 Clinical Trials

A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma
A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Biological, Radiation
Study Drug: Pembrolizumab
Study Phase: Phase 2
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Other, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
A Phase 2 Trial of Pembrolizumab Plus Bevacizumab in Patients With Metastatic Melanoma or Non-small Cell Lung Cancer With Untreated Brain Metastases
A Phase 2 Trial of Pembrolizumab Plus Bevacizumab in Patients With Metastatic Melanoma or Non-small Cell Lung Cancer With Untreated Brain Metastases
Enrollment Status: Completed
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drug: Pembrolizumab plus Bevacizumab
Study Phase: Phase 2
A Multicenter Phase 2 Trial to Evaluate Intracranial Response to Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma Who Are Anti-PD1/PD-L1 Experienced
A Multicenter Phase 2 Trial to Evaluate Intracranial Response to Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma Who Are Anti-PD1/PD-L1 Experienced
Enrollment Status: Terminated
Publish Date: June 13, 2025
Intervention Type: Drug
Study Drugs: Pembrolizumab, Lenvatinib
Study Phase: Phase 2
A Phase I Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma
A Phase I Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: June 10, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab, APX005M
Study Phase: Phase 1
A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients With Metastatic Melanoma
A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients With Metastatic Melanoma
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Biological
Study Drug: Lifileucel
Study Phase: Phase 2
A Phase II Study of MK-3475 in Patients With Advanced Merkel Cell Carcinoma (MCC)
A Phase II Study of MK-3475 in Patients With Advanced Merkel Cell Carcinoma (MCC)
Enrollment Status: Completed
Publish Date: July 05, 2023
Intervention Type: Other, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase 2 Study of MK-3475 in Patients With Metastatic Melanoma and Non-Small Cell Lung Cancer With Untreated Brain Metastases
A Phase 2 Study of MK-3475 in Patients With Metastatic Melanoma and Non-Small Cell Lung Cancer With Untreated Brain Metastases
Enrollment Status: Completed
Publish Date: March 24, 2021
Intervention Type: Drug
Study Phase: Phase 2
Stand Up to Cancer Consortium Genomics-Enabled Medicine for Melanoma (G.E.M.M.): Using Molecularly-Guided Therapy for Patients With BRAF Wild-Type (BRAFwt) Metastatic Melanoma
Stand Up to Cancer Consortium Genomics-Enabled Medicine for Melanoma (G.E.M.M.): Using Molecularly-Guided Therapy for Patients With BRAF Wild-Type (BRAFwt) Metastatic Melanoma
Enrollment Status: Completed
Publish Date: January 02, 2020
Intervention Type: Procedure, Other, Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

248 Total Publications

CTLA-4 blockade shifts the B cell repertoire towards autoimmunity.
CTLA-4 blockade shifts the B cell repertoire towards autoimmunity.
Journal: The Journal of clinical investigation
Published: September 30, 2025
View All 248 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Rohit K. Jain
Oncology | Hematology Oncology | Hematology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Rohit K. Jain
Oncology | Hematology Oncology | Hematology

New York Queens Medicine And Surgery, P.C.

5645 Main St, 
Flushing, NY 
 (60.3 miles away)
718-445-0220
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rohit Jain is an Oncologist and a Hematologist Oncology provider in Flushing, New York. Dr. Jain is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Urothelial Cancer, Muscle Invasive Bladder Cancer, Bladder Cancer, Penectomy, and Endoscopy. Dr. Jain is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Mario Sznol
Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Mario Sznol
Hematology | Oncology

Yale University

20 York St, 
New Haven, CT 
 (0.1 miles away)
203-688-2433
Experience:
43+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mario Sznol is a Hematologist and an Oncologist in New Haven, Connecticut. Dr. Sznol has been practicing medicine for over 43 years and is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Melanoma, Renal Cell Carcinoma (RCC), WT1-Related Wilms Tumor Syndromes, and Chromophobe Renal Cell Carcinoma.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Michael E. Hurwitz
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Michael E. Hurwitz
Oncology

Yale University

20 York St, 
New Haven, CT 
 (0.1 miles away)
203-785-4638
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michael Hurwitz is an Oncologist in New Haven, Connecticut. Dr. Hurwitz is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, Adult Soft Tissue Sarcoma, and Orchiectomy.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kluger's expertise for a condition
ConditionClose
  • Elite
  • Melanoma
    Dr. Kluger is
    Elite
    . Learn about Melanoma.
    See more Melanoma experts
  • Merkel Cell Carcinoma
    Dr. Kluger is
    Elite
    . Learn about Merkel Cell Carcinoma.
    See more Merkel Cell Carcinoma experts
  • Renal Cell Carcinoma (RCC)
    Dr. Kluger is
    Elite
    . Learn about Renal Cell Carcinoma (RCC).
    See more Renal Cell Carcinoma (RCC) experts
  • Distinguished
  • Brain Tumor
    Dr. Kluger is
    Distinguished
    . Learn about Brain Tumor.
    See more Brain Tumor experts
  • Chromophobe Renal Cell Carcinoma
    Dr. Kluger is
    Distinguished
    . Learn about Chromophobe Renal Cell Carcinoma.
    See more Chromophobe Renal Cell Carcinoma experts
  • Clear Cell Sarcoma
    Dr. Kluger is
    Distinguished
    . Learn about Clear Cell Sarcoma.
    See more Clear Cell Sarcoma experts
  • Familial Wilms Tumor 2
    Dr. Kluger is
    Distinguished
    . Learn about Familial Wilms Tumor 2.
    See more Familial Wilms Tumor 2 experts
  • Melanoma of the Eye
    Dr. Kluger is
    Distinguished
    . Learn about Melanoma of the Eye.
    See more Melanoma of the Eye experts
  • Metastatic Brain Tumor
    Dr. Kluger is
    Distinguished
    . Learn about Metastatic Brain Tumor.
    See more Metastatic Brain Tumor experts
View All 10 Distinguished Conditions
  • Advanced
  • Adult Soft Tissue Sarcoma
    Dr. Kluger is
    Advanced
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Lung Cancer
    Dr. Kluger is
    Advanced
    . Learn about Lung Cancer.
    See more Lung Cancer experts
  • Metastatic Uveal Melanoma
    Dr. Kluger is
    Advanced
    . Learn about Metastatic Uveal Melanoma.
    See more Metastatic Uveal Melanoma experts
  • Neuroendocrine Tumor
    Dr. Kluger is
    Advanced
    . Learn about Neuroendocrine Tumor.
    See more Neuroendocrine Tumor experts
  • Non-Small Cell Lung Cancer (NSCLC)
    Dr. Kluger is
    Advanced
    . Learn about Non-Small Cell Lung Cancer (NSCLC).
    See more Non-Small Cell Lung Cancer (NSCLC) experts
  • Olfactory Neuroblastoma
    Dr. Kluger is
    Advanced
    . Learn about Olfactory Neuroblastoma.
    See more Olfactory Neuroblastoma experts
View All 9 Advanced Conditions
  • Experienced
  • Anal Cancer
    Dr. Kluger is
    Experienced
    . Learn about Anal Cancer.
    See more Anal Cancer experts
  • Anaplastic Thyroid Cancer
    Dr. Kluger is
    Experienced
    . Learn about Anaplastic Thyroid Cancer.
    See more Anaplastic Thyroid Cancer experts
  • Basal Cell Skin Cancer
    Dr. Kluger is
    Experienced
    . Learn about Basal Cell Skin Cancer.
    See more Basal Cell Skin Cancer experts
  • Bone Tumor
    Dr. Kluger is
    Experienced
    . Learn about Bone Tumor.
    See more Bone Tumor experts
  • Follicular Thyroid Cancer
    Dr. Kluger is
    Experienced
    . Learn about Follicular Thyroid Cancer.
    See more Follicular Thyroid Cancer experts
  • Gastric Lymphoma
    Dr. Kluger is
    Experienced
    . Learn about Gastric Lymphoma.
    See more Gastric Lymphoma experts
View All 17 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2025 All Rights Reserved